In January 2025, multiple antibody-based therapies received global regulatory approvals, offering new hope for the treatment of various diseases.

In this article, we present a comprehensive overview of drugs that received their first global approvals in January 2025, along with an analysis of these therapies.

In 2024, the range of diseases treated by globally approved new drugs was diverse, with cancer and rare diseases leading in the total number of new drug approvals.

latest updates in the global new drug development field, including progress in new drug research and development.

the FDA approved several new drugs and new indications, including Roche's two blockbuster subcutaneous formulations, Eli Lilly's IL-13 antibody, and Johnson & Johnson's IL-23 antibody.

9.2-9.8 Global Drug R&D Progress & Pharmaceutical Transaction Trends.

8.26-9.1 Global Drug R&D Progress & Pharmaceutical Transaction Trends.

8.19-8.25 Global Drug R&D Progress & Pharmaceutical Transaction Trends.

This article will continue to review the antitumor targets of the GPCR family and the therapeutic drugs that have been marketed.

This article will continue to review the antitumor targets of the GPCR family and the therapeutic drugs that have been marketed.

This article will continue to review the antitumor targets of the GPCR family and the therapeutic drugs that have been marketed.

This article will inventory the anti-tumor targets in the GPCR family and the therapeutic drugs that have been marketed.